Effect of antidiabetic drug on endothelial functio
- Conditions
- ntreated type 2 diabetic patients with ischemic heart disease
- Registration Number
- JPRN-UMIN000029169
- Lead Sponsor
- Chiyukai Fukuoka Wajiro hospital
- Brief Summary
The RH-PAT and laboratory parameters, including 75 g oral glucose tolerance test, were measured at baseline and 3 months. Linagliptin reduced serum levels of glucose and insulin at 2 hours, and increased levels of active glucagon-like peptide-1 and high-molecular-weight adiponectin. Age-, sex-, and baseline-adjusted changes in logarithmic RH-PAT index (LnRHI) after 3 months were significant between groups (linagliptin, 0.135±0.097; voglibose, -0.124±0.091; P=0.047). In the linagliptin group, change in LnRHI was positively correlated with change in high-density lipoprotein cholesterol and negatively correlated with changes in both urine albumin-to-creatinine ratio and high-sensitivity C-reactive protein.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Not provided
1. Patients with liver disease (ALT or AST level is over 100IU/L, total Bil level is over 2.5mg/dl). 2. Patients with congenital heart disease. 3. Patients with highly advanced cardiac dysfunction. 4. Patients with endocrine disease. 5. Patients with malignancy or inflammatory disease. 6. Patinets with highly advanced respiratory disease (containing pulmonary arterial pulmonary hypertension. 7. Patients with cranial nerve disease or locomotor apparatus disease, and severely compromised daily life. 8. Patients with severe hypertension. 9. Patients administrated steroid or immune suppressor. 10. Patients with type1 DM or type2 DM and HbA1c (NGSP) 6.5% or more. 11. Patients during pregnancy or with possibility of pregnancy. 12. Patients administrated catecholamine. 13. Patients with symptomatic hypotension. 14. Patients with significant LVOT obstruction (Hypertrophic obstructive cardiomyopathy or aortic stenosis). 15. Patients without written consent. 16. Patients recognized inadequate by primary doctor.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes of RHI(Reactive hyperemia index)
- Secondary Outcome Measures
Name Time Method blood glucose, serum insulin level, HbA1c(NGSP), LDL, HDL, Triglyceride, total cholesterol, urine albumin/creatinine ratio, MDA-LDL, hs-CRP, IL-8, MCP-1, periostin, RAGE, HMW adiponectin, NT-pro BNP, active GLP1